OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA
Study Details
Study Description
Brief Summary
In order to compare the effectiveness between Remdesivir and Favipiravir, an observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Detailed Description
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2). Antiviral therapies are considered to be one of the COVID-19 treatments. Remdesivir and favipiravir are the antivirals recommended by Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism to inhibit virus replication, specifically by inhibiting RNA-dependent RNA polymerase (RdRp) of the virus. Several studies reported that patients who received these antivirals had a lower duration of hospitalization. However, the effectiveness comparison of remdesivir and favipiravir remains unknown.
An observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021 are collected by consecutive sampling technique, and this research was carried out at Gotong Royong Hospital Surabaya.
Study Design
Outcome Measures
Primary Outcome Measures
- Clinical manifestation [2 weeks since drug (remdesivir OR favipiravir) administration]
Oxygen needs, cough, dyspnea
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult patients (eighteen years old or above) with moderate to severe COVID-19 (categorized based on KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK. 01. 07/MENKES/413/2020);
-
Admitted to Gotong Royong Hospital Surabaya from January 2021 to August 2021;
-
Received remdesivir OR favipiravir with minimal five days of treatment
-
Not in pregnancy and lactating condition
Exclusion Criteria:
-
female patient with pregnancy and lactation
-
patient whom was passed away or forced home during two-weeks observation period
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Gotong Royong Surabaya Hospital | Surabaya | East Java | Indonesia | 60119 |
Sponsors and Collaborators
- Bernadette Dian Novita, MD.,PhD
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 148/WM12/KEPK/MHSW